IRWD
Ironwood Pharmaceuticals Inc
Halal Rating :
Last Price
$3.66
Last updated:
Market Cap
-
7D Change
-2.92%
1 Year Change
-72.15%
Company Overview
Industries
Exchange
Next Earnings Date
Ironwood Pharmaceuticals Inc is a healthcare company focused on developing and commercializing innovative gastrointestinal (GI) medicines. Their lead product is LINZESS® (linaclotide), a treatment for adults with irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). The company was founded in 1998 and is headquartered in Boston, Massachusetts.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $91.59m | $75.38m | - | $9.42m | 0.00% | 12.50% |
| June 30, 2024 | $94.4m | $76.89m | - | $7.47m | 0.00% | 9.72% |
| March 31, 2024 | $74.88m | $71.09m | - | $7.23m | 0.00% | 10.17% |
Company Impact
Help us evaluate Ironwood Pharmaceuticals Inc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.